Positive

From Nasdaq: 2025-02-14 17:54:00

Zacks Research Daily presents new reports on Apple Inc. (AAPL), Eli Lilly and Co. (LLY), Shopify Inc. (SHOP), and micro-cap stock ImmuCell Corp. (ICCC). Apple reports strong growth in Services revenues with over 1 billion paid subscribers. Eli Lilly’s Q4 earnings beat estimates, driven by demand for GLP-1 drugs. Shopify is benefiting from a growing merchant base. ImmuCell reports 11% year-over-year sales growth driven by its First Defense line targeting the scours prevention market.

Apple expects low to mid-single digits revenue growth in the March quarter with low double-digit growth in Services segment. Eli Lilly’s new drugs like Kisunla and Omvoh contributed significantly to top-line growth in 2024. Shopify’s new merchant-friendly tools are winning new merchants regularly. ImmuCell’s Re-Tain aims to disrupt the subclinical mastitis market with FDA approval nearing.

Other noteworthy reports include The PNC Financial Services Group, Inc. (PNC), Exelon Corp. (EXC), and PTC Inc. (PTC). PNC’s inorganic and strategic growth initiatives are expected to support its profitability. Exelon’s decoupling mechanism mitigates load fluctuation impact. PTC is benefiting from momentum in PLM and CAD solutions. This is just a glimpse of the latest research reports from Zacks Research Daily.

Experts have distilled 7 elite stocks from the current list of Zacks Rank #1 Strong Buys, deeming them “Most Likely for Early Price Pops.” Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. Be sure to give these 7 stocks your immediate attention.



Read more at Nasdaq: Top Stock Reports for Apple, Eli Lilly & Shopify